Fig. 2
From: Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients
Nivolumab therapy modifies the alterations of CD26high frequencies. Box plots showing the median (25th; 75th percentile) distribution of CD26neg (A), CD26int (B), and CD26high (C) in a sub-cohort of 33 melanoma patients at baseline and after 12 weeks (W1) of nivolumab treatment. Representative dot plots illustrating CD26 subsets melanoma patients at W0 and W1 are depicted in D and E respectively